News

Published on 29 Jun 2022 on Zacks via Yahoo Finance

Graybug (GRAY) to Review Strategic Alternatives, Stock Up


Article preview image

Graybug Vision, Inc. GRAY announced that its board of directors is willing to conduct a comprehensive review of strategic options and alternatives focused on maximizing shareholders’ value of the company.

As a part of this strategic review, Graybug is considering a potential sale of the company apart from evaluating other alternatives like an acquisition, merger, divestiture of assets, and private placement of equity securities, among others.

Shares of Graybug were up 35.4% on Tuesday following the announcement of the news. The stock has plunged 39.9% so far this year compared with the industry’s decline of 21.7%.

NASDAQ.GRAY price evolution

Want to become a better investor?

Start tracking your investments with Statfolio

Sign up for free
Related News
Individual investors are Graybug Vision, Inc.'s (NASDAQ:GRAY) biggest owners and were hit after...

Key Insights The considerable ownership by individual investors in Graybug Vision indicates that ...

Simply Wall St. via Yahoo Finance 20 Mar 2023

Graybug Vision Agrees To Merge With Inflammatory Disease-Focused Biopharma

Graybug Vision Inc (NASDAQ: GRAY) and CalciMedica Inc (CalciMedica) have announced a definitive m...

Benzinga via Yahoo Finance 22 Nov 2022

Graybug (GRAY) to Review Strategic Alternatives, Stock Up

Graybug Vision, Inc. GRAY announced that its board of directors is willing to conduct a comprehen...

Zacks via Yahoo Finance 29 Jun 2022

The Daily Biotech Pulse: Adcom Recommends Additional Trials For Lilly's Partnered Cancer Drug,...

Here's a roundup of top developments in the biotech space over the last 24 hours: Eli Lilly And C...

Benzinga 11 Feb 2022

The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations,...

Biotech stocks reversed course and closed the week ended Nov. 5 lower, squandering the gains notc...

Benzinga 8 Nov 2021

Graybug Vision Posts Six-Month Extension GB-102 Data Of Wet AMD Trial

Graybug Vision Inc (NASDAQ: GRAY) has provided a full-data analysis from the 18-month Phase 2b AL...

Benzinga via Yahoo Finance 2 Oct 2021

The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody...

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks

Benzinga via Yahoo Finance 30 Sep 2021

The Daily Biotech Pulse: AbbVie's Migraine Drug OK'd By FDA, Amicus Spins Off Gene Therapy Business,...

Here's a roundup of top developments in the biotech space over the last 24 hours. Click here fo...

Benzinga via Yahoo Finance 29 Sep 2021

53 Biggest Movers From Friday

Gainers Innate Pharma S.A. (NASDAQ: IPHA) shares surged 47.1% to settle at $6.15 on Friday after ...

Benzinga via Yahoo Finance 9 Sep 2021

Is OFS Capital Corp (OFS) A Good Stock To Buy?

Hedge Funds and other institutional investors have just completed filing their 13Fs with the Secu...

Insider Monkey via Yahoo Finance 24 Jun 2021